1. Introduction {#sec1}
===============

The Australian sheep blowfly (*Lucilia cuprina)* is an important ecto-parasite that causes fly strike, which has significant health and welfare, as well as economic, impacts on the sheep industry in Australia ([@bib63]). The female blowfly is attracted to the sheep by odours, particularly those associated with bacterial infections in damp fleece, and lays eggs ([@bib69]). The developing larvae feed on the sheep, causing severe tissue damage, toxaemia, and in some cases, death. The consequent loss of livestock, costs of preventative and curative chemical treatments, and animal welfare issues place significant economic burdens on livestock enterprises ([@bib43]). The blowfly has developed resistance to various classes of chemical insecticides used for its control, including organochlorines, organophosphates, the benzoyl-phenyl urea diflubenzuron ([@bib46], [@bib63]) as well as the triazine cyromazine ([@bib47]). Only two preventative blowfly control chemicals, the macrocyclic lactone ivermectin and the cyanopyrimidine dicyclanil, remain effective with no resistance yet reported. There is therefore a need to identify new chemical classes of insecticides, preferably with different target proteins, to control this important parasitic insect.

Histone deacetylase inhibitors (HDACi) have been recognised as therapeutic targets in cancer for many years ([@bib13]), with a number in clinical use or clinical trials as anti-cancer drugs. They have also been studied extensively over recent years for their potential in chemotherapy for parasitic diseases of humans, including malaria, toxoplasmosis, trypanosomiasis, schistosomiasis and leishamaniasis ([@bib2], [@bib3]; [@bib52]). HDAC enzymes have been studied extensively in the model dipteran insect *Drosophila* with respect to their roles in longevity and memory formation ([@bib19], [@bib58], [@bib65]), with a *Drosophila* model providing experimental evidence to highlight HDACi as potential therapeutics for the treatment of Huntington\'s disease ([@bib66]). However, only a single study has reported the insecticidal activity of an HDACi against this fly species, with [@bib56] noting that trichostatin caused lethality during larval development. The potential for HDACi as insecticides was recently highlighted by [@bib39] who showed that trichostatin and suberoylanilide hydroxamic acid (SAHA) were able to inhibit the development of sheep blowfly larvae *in vitro*. That report also highlighted similarities and differences in amino acid sequences of blowfly and human HDAC enzymes, with differences particularly noted between species for the Class II enzymes HDAC4 and 6, and the Class IV HDAC11, raising the possibility of identifying insect-specific inhibitors.

The present study expands on our earlier report of insecticidal activity for trichostatin and SAHA ([@bib39]) by examining other HDACi with different chemical structures and mechanisms of action. We focus on hydroxamic acids since these are the best known group of HDACi, but also include inhibitors with different chemical components, such as benzamides, thioesters, thiolates, disufides, cyclic depsi- and tetra-peptides, fatty acids, and sesquiterpene lactones ([Table 1](#tbl1){ref-type="table"}). We measure the effects of these HDACi on the development of blowfly larvae (larval growth rate and pupation rate) and on the HDAC enzyme activity of nuclear protein extracts prepared from blowfly eggs. We also compare these results with reported inhibitory activities against human HDAC enzymes as an initial step towards identification of insect-specific inhibitors.

2. Materials and methods {#sec2}
========================

2.1. Insects and chemicals {#sec2.1}
--------------------------

The *L. cuprina* used in this study were from the laboratory reference drug-susceptible LS strain, derived from collections made in the Australian Capital Territory (Canberra, Australia) over 40 years ago. This strain has been maintained in a laboratory since that time (in Canberra for 30 years, and then at CSIRO and University of Queensland laboratories in Brisbane for the last 10 years), and has no history of exposure to insecticides. Adult flies were maintained at 28 °C and 80% relative humidity with a daily photoperiod of light 16 h and dark 8 h. Adults were fed a diet of sugar and water, while larvae were raised on a wheatgerm culture medium ([@bib68]). Protein meals (bovine liver) were provided on days 4 and 8 after adult eclosion in order to prime adult flies for subsequent egg-laying. For provision of eggs for bioassays, liver was placed into cages of gravid flies for a period of two hours (12 p.m. until 2 p.m.). The liver was then removed and kept at room temperature overnight. At 10 a.m. the next morning, assays were established using the newly-hatched larvae.

HDACi were synthesized by reported procedures or obtained from commercial sources ([Table 1](#tbl1){ref-type="table"}). The structures are shown in [Supplementary Figs. 1--4](#appsec1){ref-type="sec"}. Stock solutions for use in larval bioassays were prepared in ethanol at a concentration of 1 mg/mL. In cases where the compound did not dissolve at this concentration the solutions were further diluted 2-fold with ethanol until no precipitate was evident (to give stocks at 0.5 or 0.25 mg/mL). Exceptions were CUDC-907 and MC1568 which required dilution to a concentration of 0.05 mg/mL. The commercial insecticide stocks used as controls were prepared at 1 mg/mL in water (cyromazine and dicyclanil) or acetone (diflubenzuron). Stock solutions of HDACi for use in nuclear extract HDAC enzyme assays were prepared at 1 mg/mL in DMSO.

2.2. Blowfly larval bioassay {#sec2.2}
----------------------------

The effects of HDACi on the growth of blowfly larvae was assessed using a bioassay system in which larvae were allowed to develop on cotton wool impregnated with the compounds at various concentrations (modified slightly from [@bib38]). Briefly, 4 mL aliquots of HDACi or commercial insecticide solutions were added to cotton wool plugs and the solvent (4 mL of either ethanol, acetone, or water) was allowed to evaporate overnight. Control containers were prepared by addition of 4 mL of the relevant solvent to the cotton wool. The next day (Day 0 of the assay), a sheep serum-based medium (80 g/L yeast extract (Merck), 1.6 mg/mL tylosin (Sigma) in lamb serum (Life Technologies) buffered with 35 mM KH~2~PO~4~, pH7.5) was added to the cotton wool, and groups of 50 freshly-hatched larvae (prepared as described in section [2.1](#sec2.1){ref-type="sec"}, above) were placed onto the cotton wool. The assay pots were placed at 28 °C. In order to calculate mean larval weight at the beginning of the drug exposure period, two groups of 100 larvae were collected, blotted dry on paper towel, weighed and discarded on Day 0. After 24 h (Day 1), 3 larvae were removed from each container, weighed, and discarded. The remaining larvae were fed with 1 mL of nutrient medium on Day 1, and then 2 mL on each of Days 2 and 3. Late on Day 4, the containers were placed into larger pots with a layer of sand at the base to serve as a medium for pupation, and returned to the incubator. Pupae were recovered from the sand on sieves on Day 9, and counted.

Each compound was examined at four or five serially diluted (5-fold) concentrations. Each experiment consisted of a single container at each concentration of HDAC inhibitor or insecticide, alongside 4 control assays. Two separate experiments were performed for each compound. The effect of the compounds on larval development was defined in two ways:i)Larval weight gain in first 24 h; the total weight gain of the 3 larvae sampled on Day 1 was expressed as a percentage of the mean of the weight gain of the 3 larvae sampled from each of the 4 control containers (weight gain was calculated by difference using weight on Day 1 and the mean weight of larvae on Day 0);ii)Pupation rate; the number of pupae in each drug-treated container was expressed as a percentage of the mean number of pupae in the 4 control containers.

The larval weight and pupation rate dose-response data were analysed with GraphPad Prism^®^ software using non-linear regression, with the 'variable slope' option selected, in order to calculate IC~50~ values (with 95% Confidence Intervals) representing the concentration of inhibitor required to reduce the larval weight gain or pupation rate to 50% of that measured in control (no drug) treatments.

2.3. Nuclear extract preparation {#sec2.3}
--------------------------------

Nuclear extracts were prepared from blowfly eggs (0.5 g) using a Nuclear Extraction kit (Millipore, USA) following the manufacturer\'s protocol with some modifications. The chorion was removed by soaking for 80 s in a solution of bleach (2% v/v), followed by centrifugation to sediment the eggs. The eggs were washed 3 times in ice cold PBS. Complete Mini Protease Inhibitor (Roche, Basel Switzerland) in PBS was added to the washed eggs before disrupting them by hand with a plastic pestle. The disrupted eggs were centrifuged at 250*g* for 1 min at 4 °C, and supernatant removed. The egg cell pellet was washed with 1000 μL of ice cold PBS, resuspended by inversion, centrifuged at 1000*g* for 5 min at 4 °C, and the supernatant removed. This wash step was repeated a further 2 times. The cells were then disrupted by drawing 5 times through a 21 g needle fitted to a 1 mL syringe. The suspension was centrifuged at 8000*g* for 20 min at 4 °C, the supernatant removed and discarded, and the pellet retained (nuclear portion). The nuclear pellet was resuspended in 2/3 of the original cell pellet volume of ice cold nuclear extraction buffer (containing 0.5 mM DTT and protease inhibitor cocktail, Millipore, Temecula). The solution was placed on low speed roller for 1 h at 4 °C, then centrifuged at 16000*g* for 5 min at 4 °C, and the supernatant (the nuclear extract) transferred to a new tube. The protein concentration was measured by the method of [@bib11] using the Bio-Rad protein assay reagent, and bovine serum albumin as a standard. The extract was then aliquoted into separate tubes, snap-frozen in liquid nitrogen, and stored at −80 °C.

2.4. HDAC enzyme assay {#sec2.4}
----------------------

A fluorometric assay kit (Sigma-Aldrich, USA) was used to measure HDAC enzyme activity in blowfly nuclear extracts, as described in the kit instructions, except that the volumes of all reagents were reduced to give a total assay volume of 27.5 μL. Each assay contained approximately 15 μg of nuclear extract protein. HDAC activity was measured in the presence or absence of HDACi. Control assays were also run in the presence of 1.25 μM trichostatin in order to calculate the amount of fluorescent product that was derived from a trichostatin-inhibitable reaction, that is, the amount of product derived from the action of HDAC enzymes alone. The assay was performed using a series of at least 4 serially-diluted working solutions of each HDACi. Duplicate assays were performed at each HDACi concentration. The fold dilutions used to generate each working solution series varied from 2--fold to 10-fold, and were set (based on initial dose-finding experiments) in order to provide a dose response curve consisting of 4--6 data points. The % inhibition of HDAC activity was calculated for each concentration of HDACi added to the reaction. The enzyme assay dose-response data were analysed with GraphPad Prism^®^ software using non-linear regression, with the 'variable slope' option selected, in order to calculate IC~50~ values (with 95% Confidence Intervals) representing the concentration of inhibitor required to reduce the HDAC activity of the nuclear extract by 50%.

2.5. Larval and enzyme assay comparisons {#sec2.5}
----------------------------------------

We performed a non-parametric (Spearman) correlation analysis in GraphPad Prism^®^ in order to examine the relationship between the effects of HDACi in inhibiting blowfly larval development and inhibiting nuclear extract HDAC enzyme activity. In addition, in order to examine the relationship between the blowfly bioassay data and the reported inhibitory effects of the HDACi against specific human HDAC enzymes, we performed a correlation analysis using the bioassay data and IC~50~ values reported in the scientific literature for the HDACi against human HDAC enzymes (see [Supplementary Table 1](#appsec1){ref-type="sec"}). While blowflies are known to possess HDAC1, 3, 4, 6 and 11, ([@bib39]), the analysis was only performed with human HDAC1, 3, 4 and 6 as insufficient inhibition data was available for an analysis of inhibitory effects on human HDAC11. For the correlation analysis, we grouped HDAC 1 and 3 together as Class I HDAC enzymes, and HDAC4 and 6 together as Class II HDAC enzymes.

3. Results {#sec3}
==========

Forty HDACi compounds were investigated for inhibition of the growth of blowfly larvae, with their activities reported in [Table 2](#tbl2){ref-type="table"} as inhibition of larval weight gain and pupation (μg/assay). For comparison, the toxicities of three commercial blowfly insecticides are also reported in [Table 2](#tbl2){ref-type="table"}. The most potent inhibitor of blowfly larval growth was the depsipeptide romidepsin, which was more potent, or as potent as, the commercial insecticides: 10-fold more potent than cyromazine, 2-fold more potent than diflubenzuron, and equipotent with dicyclanil ([Table 2](#tbl2){ref-type="table"}, [Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}). The most potent hydroxamic acids were trichostatin, CUDC-907, AL179-3b and AR-42: approximately 10-fold less potent than cyromazine, and approximately 50--100--fold less potent than diflubenzuron and dicyclanil. Also showing marked activity (IC~50~ \< 100 μg/assay) were the thioester compound KD5170, the disulfide compound Psammaplin A (which is a prodrug that forms a thiolate much like romidepsin), and the cyclic tetrapeptide apicidin. Many of the compounds, including 13 of the hydroxamic acids, the two fatty acids (valproic acid and AN-9), and the single sesquiterpene lactone (parthenolide) showed little or no insecticidal activity (IC~50~ \> 1000 μg/assay).

Comparisons between the larval weight gain and pupation IC~50~ for the commercial insecticides showed that the two values were within 2-fold of each other. For 7 of the 8 most active HDACi (larval IC~50~ \< 100 μg/assay, [Fig. 2](#fig2){ref-type="fig"}), the variation between the larval and pupation IC~50~ values was also within a 2-fold range. The two values were approximately equal for CUDC-907 and AR-42, while within 2-fold for trichostatin, AL1179-3b, romidepsin and KD5170. On the other hand, the pupation IC~50~ for apicidin was 6-fold higher than for larval weight gain.

The HDACi were also investigated for inhibition of HDAC activity in nuclear extracts from blowfly eggs ([Table 3](#tbl3){ref-type="table"}), with representative dose-response curves shown in [Fig. 3](#fig3){ref-type="fig"} (some of the compounds shown in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"} were not examined in nuclear extract assays as insufficient material was available). As with the insecticidal assays, romidepsin was the most potent inhibitor of HDAC activity. This compound was approximately 600-fold more potent than the second most-active compound, quisinostat, and about 1000-fold more potent than trichostatin. The hydroxamic acids that were the most active in the blowfly larval bioassay were among the most potent enzyme inhibitors (IC~50~ 0.016--0.212 μM for trichostatin, CUDC-907 and AR-42). A number of hydroxamic acids that were significant HDAC enzyme inhibitors in the nuclear extracts (IC~50~ \< 0.3 μM) had low potency in the larval bioassay (e.g. panobinostat, givinostat, belinostat: larval IC~50~ 295, 477, and 740 μg/assay, respectively). Among the other compounds highlighted above for their insecticidal activity (from [Fig. 2](#fig2){ref-type="fig"}), all showed significant potency in inhibiting the HDAC enzyme activity of the nuclear extract (all IC~50~ \< 1 μM).

The relationship between larval bioassay IC~50~ and nuclear extract HDAC inhibition IC~50~ is shown in [Fig. 4](#fig4){ref-type="fig"} ([Fig. 4](#fig4){ref-type="fig"}A shows whole data set, [Fig. 4](#fig4){ref-type="fig"}B shows data points with extract HDAC inhibition IC~50~ \< 2.0 μM only). Analysis of the whole data set ([Fig. 4](#fig4){ref-type="fig"}A), revealed that the two assay parameters were significantly correlated (Spearman correlation coefficients shown on Figure panels). Despite this, some differences between the two measurements were apparent, with larval weight IC~50~ values of 1000 (n = 14) corresponding to a range of nuclear extract activities from 0.032 μM (CUDC-101) to \> 100 μM (six compounds). Importantly, low larval weight IC~50~ values (\<100 μg/assay) did not occur alongside high nuclear extract IC~50~. [Fig. 4](#fig4){ref-type="fig"}B illustrates this, with the most active insecticidal compounds all being potent inhibitors of HDAC activity in blowfly nuclear extracts (IC~50~ \< 0.5 μM).

We also examined the relationship between published IC~50~ values for inhibition of human HDAC enzymes by the HDACi used in this study with their activity in inhibiting blowfly larval development. The analysis was restricted to just the human HDACs that corresponded to the Class I and Class II HDAC enzymes present in the blowfly, namely HDAC1 and 3 (Class I) and HDAC4 and 6 (Class II). The published data on the inhibition of human HDAC11 (corresponding to the other HDAC present in the blowfly) was not extensive enough with respect to the HDACi examined in the present study (see [Supplementary Table 1](#appsec1){ref-type="sec"}) to allow for a separate analysis of this Class IV HDAC. The relationship between the blowfly bioassay data for each HDACi and the reported enzyme inhibition IC~50~ values against the Class I and II human HDAC enzymes are shown in [Fig. 5](#fig5){ref-type="fig"}. The two parameters were significantly correlated for the Class I enzymes, but not for the Class II enzymes. However, even though a significant correlation existed for Class I enzymes across the whole data set, a number of compounds that were potent inhibitors of the human Class I enzymes showed no insecticidal activity (IC~50~ \> 1000 μg/assay). Similarly, some potent human Class II HDAC inhibitors showed no insecticidal activity.

4. Discussion {#sec4}
=============

The present study has examined the ability of a number of known HDACi to inhibit the growth and development of blowfly larvae, and correlated this effect with their ability to inhibit the HDAC activity of nuclear extracts prepared from blowfly eggs. There was a significant correlation, suggesting that their insecticidal activity was likely due to the inhibition of blowfly HDAC enzymes. Romidepsin was a very potent inhibitor of both blowfly larval growth and blowfly HDAC activity, the potency being equivalent to or greater than commercial blowfly insecticides. In addition, we have shown that a number of other HDACi have significant insecticidal activity against blowfly larvae, including hydroxamic acids (Trichostatin, CUDC-907, AL1179-3b, AR-42), a thioester (KD5170), a disulphide (Psammaplin A) and a cyclic tetrapeptide with a zinc-binding ketone (Apicidin).

While these HDACi validate the concept of a potentially valuable new target for insecticides, we are not advocating the use of the particular compounds reported herein as commercial insecticides. They would be too expensive to be economically viable for any livestock or agronomic production setting. Moreover, most of the more potent HDACi described are also potent inhibitors of human HDACi (IC~50~ nM - μM) and might prove cytotoxic in sheep and unacceptable in terms of human consumption of sheepmeat. Hence, while our demonstration of the potent insecticidal activity of a number of HDACi helps to prove the concept that HDACi may be effective insecticides, issues associated with cost of production and target pest selectivity need to be solved next.

Romidepsin is a prodrug that is first activated by reduction of its disulfide to the free thiol that can then bind to the catalytic Zn^2+^ in HDAC enzymes. Thiols or thiolates have a much lower binding affinity for Zn^2+^ than hydroxamic acids. The higher potency of romidepsin involves either a highly complementary fit of the conformationally constrained cyclic depsipeptide component of romidepsin with the enzyme, or higher metabolic stability than the hydroxamates. Apicidin is another compound with significant insecticidal activity ([Table 2](#tbl2){ref-type="table"}) which also has a rigid cyclic tetrapeptide component that adds affinity to the relatively weak interaction between its ketone component and zinc. Interestingly, [@bib17] found that romidepsin inhibited the growth of asexual stage *Plasmodium falciparum* (IC~50~ 0.1 μM), the bloodstream form *Trypanosoma brucei* parasites (IC~50~ 0.035 μM), and was a potent inhibitor of HDAC enzyme activity in *P. falciparum* nuclear extracts (IC~50~ 0.9 nM).

In contrast, most hydroxamic acid based inhibitors derive their affinity from zinc chelation which sometimes compensates for a suboptimal fit between the remaining features of the inhibitor and the enzyme active site. The 31 hydroxamic acids examined here have considerable structural diversity and are mostly potent inhibitors of human HDACs. They show quite a range of inhibitory potencies against blowfly larval growth over two log units ([Table 2](#tbl2){ref-type="table"}). Most of the hydroxamate-based inhibitors were derived from 4-aminopyrimidine or 4-aminobenzene hydroxamic acids, which confer an extended linear shape to the fragment projecting towards Zn^2+^ in the enzyme. Trichostatin has a similarly rigid linear structure due to its highly conjugated olefin components. Other active inhibitors with a linear structure due to an aromatic group in conjugation with a double bond and hydroxamate are the cinnamic acid hydroxamates, panobinostat & pracinostat. The potent suberoylhydroxamates (AL1179-3b & PG50) have a more flexible linear zinc-binding extension like the similarly flexible but simpler parent compound SAHA, but exhibit superior activity attributed to their branched capping group that likely makes multiple interactions with the enzyme. PG50 was developed as a selective inhibitor of human HDAC6 ([@bib24]), however it seems to be a class I HDACi in the blowfly possibly suggesting its capping groups are too small to influence selectivity as the other hydroxamate inhibitors known to specifically inhibit human HDAC6 (tubacin & tubastatin A) were inactive in the blowfly bioassay. The reasons why other hydroxamates were inactive is not clear, but they do show how selectivity between highly homologous enzymes can be achieved, in this case away from blowfly and towards human. In principle this trend might be reversed with new compounds. Clues derived from the capping cyclic peptide groups away from the zinc-binding moieties of romidepsin and apicidin may steer the development of new compounds with greater potency and selectivity for the target enzyme to make better and safer insecticides.

Two aspects of the time course of insecticidal effects are important for blowfly control. Firstly, effective insecticides must kill, or inhibit the growth of early stage larvae before they can damage the host. Secondly, where the initial effects are inhibitory rather than lethal, they must persist over at least several days and then kill the larva to prevent it recovering and developing to damage the host. A comparison of the two bioassay IC~50~ values is informative with respect to these time course considerations. The commercial insecticides show a pupation IC~50~ that is similar (within two fold) to the 24 h weight gain IC~50~, consistent with the larvae not recovering from an initial growth inhibition phase. This was also observed for seven of the eight HDACi highlighted in [Fig. 2](#fig2){ref-type="fig"}. Apicidin on the other hand showed a pupation IC~50~ value almost 6-fold greater than the weight gain IC~50~, indicating some recovery of larvae after the initial inhibitory effects on growth.

A number of compounds showed potent inhibition of the nuclear extract HDAC activity, but only low or no activity in the larval bioassay (for example: nuclear enzyme assay CAY10603 IC~50~ 0.165 μM, CUDC-101 0.0317 μM *vs* larval bioassay IC~50~ \> 1000 μg/assay). This is likely due to poor uptake or low stability of the compounds in the larval assay. There are likely to be differences between the various compounds examined in terms of uptake across the larval cuticle (trans-cuticular uptake) and across the intestinal membranes (following ingestion), as well as access to the cellular target following uptake. Some of the compounds are likely to be metabolised to a greater degree than others by the blowfly xenobiotic-detoxification systems, which include esterases ([@bib14]), cytochromes P450 ([@bib37]) and glutathione transferases ([@bib35]).

Potency against human class I HDAC enzymes generally correlated with insecticidal activity, but some potent inhibitors of human Class I HDAC (IC~50~ \< 0.10 μM) showed no insecticidal activity. This may be due to factors associated with uptake and stability of the compounds in the bioassay, as well as differences in the intrinsic level of interaction of the compounds with the human enzymes compared to the equivalent blowfly HDAC enzymes. [@bib39] described some differences in the amino acid residues between the human and blowfly Class I HDACs, with catalytic domain amino acids showing 86% and 73% identities between human and blowfly HDAC1 and 3, respectively. The relationship between inhibitory effects of HDACi on human Class II HDACs and their insecticidal activity was poor, with no significant correlation between the two parameters. The catalytic domain amino acids differ to a much greater extent between the human Class II HDACs and their blowfly equivalents compared to the Class I comparisons, with % identities of 61%, 47% and 50% for HDAC 4 and the two catalytic domains of HDAC6, respectively, between the human and blowfly ([@bib39]). Hence, HDACi of human and blowfly Class II enzymes may show a lower level of relatedness than among inhibitors of Class I enzymes from the two species. The lack of correlation for Class II HDACs may be favourable for potential identification of more insect-specific HDACi that interact specifically with the blowfly Class II enzymes, while showing less inhibition of the human Class II enzymes. However, more information on the different roles played by the blowfly Class I and II HDAC enzymes is required before a preferred target HDAC Class or individual enzyme can be determined. [@bib20] found that RNAi --mediated silencing of *Drosophila* HDACs 1 and 3 resulted in inhibitory effects on growth curves for *Drosophila* Schneider (S2) cell lines, whereas silencing of HDACs 4, 6 and 11 did not inhibit cell growth, suggesting more important roles for the two Class I enzymes in cell viability. [@bib16] reported that *Drosophila* HDAC6 loss-of-function mutant flies were viable and fertile, suggesting that this enzyme may not be essential for the development of this fly species.

In conclusion, the present study shows that HDACi from various chemical groups can substantially inhibit the development of blowfly larvae. In particular, romidepsin was at least equipotent with the major commercial blowfly insecticides, supporting the concept of inhibiting blowfly HDAC enzymes to produce new insecticides for preventing infection by sheep blowfly, and to potentially control other insects. There is a great deal of interest currently in developing HDAC inhibitors for use in chemotherapy against other human parasitic disease -- malaria, toxoplasmosis, trypanosmiasis, schistosomiasis and leishmaniasis ([@bib2], [@bib3], [@bib4], [@bib33], [@bib26], [@bib17], [@bib52]). A focus of these studies is the identification of HDACi that show selectivity for the parasite HDAC enzymes over the human enzymes. Similarly, further work on developing HDAC inhibitors as potent insecticides could focus on identifying insect-specific inhibitors, but at the very least should focus on producing HDACi that are cheap to manufacture and market as prospective insecticides.
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![Effects of HDACi (coloured solid symbols and lines; named in key) and commercial insecticides (open symbols dashed lines; cyromazine ◊, diflubenzuron □, dicyclanil ○) on the growth of blowfly larvae. Each data point represents mean ± SE, n = 2 assays at each compound concentration. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr1){#fig1}

![Structures of HDACi with the most potent inhibition of blowfly larval development (larval weight gain IC~50~ \< 100 μg/assay).](gr2){#fig2}

![Effects of HDACi (named in key) on HDAC activity of nuclear extracts prepared from blowfly eggs. Each data point represents mean ± SE, n = 2 assays at each compound concentration.](gr3){#fig3}

![Relationship for HDACi in inhibiting blowfly larval development (larval weight gain IC~50~) versus blowfly HDAC activity (nuclear extract IC~50~). A: whole data set (n = 34), with Spearman correlation coefficient and *P* value; data points at 100 μM for nuclear extract inhibition and/or 1000 μg/assay for larval weight were measured as \> 100 and \> 1000, respectively. B: Only the most potent inhibitors of HDAC activity (IC~50~ \< 2.0 μM, n = 16), with Spearman correlation coefficient and *P* value; circled data points are for romidepsin, TSA, CUDC-907, AR 42, KD5170 and Psammaplin A.](gr4){#fig4}

![Relationship for HDACi in inhibiting larval development (larval weight gain IC~50~) versus human Class I enzymes (HDAC1 ○, HDAC3 ■) (A) (n = 45), and human Class II enzymes (HDAC4 ●, and HDAC6 Δ) (B) (n = 37). Spearman correlation coefficients and *P* values shown. Data points at 20 μM for human enzyme inhibition and/or 1000 μg/assay for larval weight were measured as \> 20 and \> 1000, respectively.](gr5){#fig5}

###### 

HDAC inhibitors and insecticides used.

Table 1

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug group                               Compound                                          Human HDACs Inhibited                                                       References           Source
  ---------------------------------------- ------------------------------------------------- --------------------------------------------------------------------------- -------------------- --------------------
  **1) HDAC inhibitors**                                                                                                                                                                      

  Hydroxamic acids                         Trichostatin                                      Class I and II                                                              [@bib74]             Selleckchem

  CUDC-907                                 Class I and II; also class I PI3K                 [@bib59]                                                                    Selleckchem          

  AL1179-3b                                Class I and II                                    [@bib32]                                                                    synthesized          

  AR-42                                    Class I and II                                    [@bib48], [@bib71]                                                          ApexBio              

  Quisinostat                              Class I and II                                    [@bib5]                                                                     Selleckchem          

  PG50                                     HDAC6                                             [@bib24]                                                                    synthesized          

  Nexturastat A                            HDAC6                                             [@bib10]                                                                    ApexBio              

  AL1179-84                                Class I and II                                    [@bib32]                                                                    synthesized          

  Panobinostat                             Class I and II                                    [@bib6], [@bib61]                                                           ApexBio              

  Pracinostat (SB939)                      Class I and II                                    [@bib53]                                                                    ApexBio              

  SBHA                                     Class I and II                                    [@bib62]                                                                    ApexBio              

  AL-1179-85                               Class I and II                                    [@bib32]                                                                    synthesized          

  SAHA (Vorinostat)                        Class I and II                                    [@bib62], [@bib30]                                                          ApexBio              

  Givinostat                               Class I and II                                    [@bib45]                                                                    ApexBio              

  M344                                     Class I and II                                    [@bib28]                                                                    ApexBio              

  Resminostat                              Class I and II                                    [@bib50]                                                                    ApexBio              

  Belinostat                               Class I and II                                    [@bib57], [@bib70]                                                          ApexBio              

  Naphthohydroxamic acid                   HDAC8                                             [@bib41]                                                                    Sigma-Aldrich        

  Droxinostat                              Class I and II                                    [@bib73]                                                                    ApexBio              

  CAY10603                                 Class I and II                                    [@bib40]                                                                    Santa Cruz Biotech   

  VAHA (Valproic acid hydroxamate)         Class I and II                                    [@bib18]                                                                    Santa Cruz Biotech   

  MC-1568                                  Class IIa                                         [@bib49]                                                                    Selleckchem          

  ABHA                                     Class I and II                                    [@bib1]                                                                     synthesized          

  NW58                                     HDAC 1& 2                                         [@bib72]                                                                    synthesized          

  Tubacin                                  HDAC6                                             [@bib12]                                                                    Selleckchem          

  HPOB                                     HDAC6                                             [@bib44]                                                                    ApexBio              

  BRD73954                                 HDAC6 and HDAC8                                   [@bib54]                                                                    ApexBio              

  CUDC-101                                 Class I and II\                                   [@bib42]                                                                    ApexBio              
                                           EGFR (epidermal growth factor receptor)\                                                                                                           
                                           HER2 (human epidermal growth factor receptor 2)                                                                                                    

  Rocilinostat                             HDAC6                                             [@bib64]                                                                    Selleckchem          

  Tubastatin A                             HDAC6                                             [@bib12]                                                                    ApexBio              

  PCI-34051                                HDAC8                                             [@bib7]                                                                     Santa Cruz Biotech   

  Cyclic depsipeptide                      Romidepsin                                        Class I                                                                     [@bib22], [@bib8]    ApexBio

  Benzamides                               Entinostat                                        Class I                                                                     [@bib29]             ApexBio

  Mocetinostat                             Class I                                           [@bib21]                                                                    ApexBio              

  Thioester                                KD5170                                            Class I and II                                                              [@bib27]             ApexBio

  Disulfide                                Psammaplin A                                      Class I                                                                     [@bib9], [@bib34]    Santa Cruz Biotech

  Thiolate                                 TCS HDAC620b                                      HDAC6                                                                       [@bib67]             ApexBio

  Cyclic tetrapeptide                      Apicidin                                          HDAC1; Anti-protozoan activity                                              [@bib31], [@bib15]   ApexBio

  Fatty acids                              Valproic acid                                     Class I and II                                                              [@bib55], [@bib18]   Sigma-Aldrich

  Pivanex (AN-9)                           Histone hyperacetylation                          [@bib60]                                                                    Sigma-Aldrich        

  Sesquiterpene lactone                    parthenolide                                      Depletes HDAC1 but not other class I/II HDACs                               [@bib23]             Santa Cruz Biotech

  **2) Commercial blowfly insecticides**                                                                                                                                                      

  Pyrimidine                               Dicyclanil                                        Insect growth regulator: mechanism unknown                                  --                   Fluka

  Diamino-triazine                         Cyromazine                                        Insect growth regulator: mechanism unknown, affects cuticle extensibility   [@bib36]             Chem Service

  Benzoyl phenyl urea                      Diflubenzuron                                     Insect growth regulator: inhibits chitin synthesis                          [@bib25]             Chem Service
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Effects of HDACi and commercial insecticides on the development of blowfly larvae.

Table 2

  Drug group                               Compound        Blowfly bioassay                                
  ---------------------------------------- --------------- ------------------ --------------- ------------ ----------------
  **1) HDAC inhibitors**                                                                                   
  Hydroxamic acids                         Trichostatin    10.4               5.3--20.4       20.6         16.0--26.6
  CUDC-907                                 12.2            6.1--24.5          13.8            7.5--25.5    
  AL1179-3b                                13.9            7.3--26.2          20.0            14.6--27.3   
  AR-42                                    34.0            26.9--43.7         28.0            20.1--38.3   
  Quisinostat                              100             39--260            274             149--501     
  PG50                                     101             26--388            \>200                        
  Nexturostat                              137             68--279            \>1000                       
  AL1179-84                                254             79--816            918             619-1360     
  Panobinostat                             295             162--539           393             173--895     
  Pracinostat                              302             110--834           \>1000                       
  SBHA                                     356             215--588           550             405--747     
  AL-1179-85                               380             90-1607            863             746-1000     
  SAHA                                     434             247--763           \>1000                       
  Givinostat                               477             157-1444           \>1000                       
  M344                                     490             294--804           890             632-1257     
  Resminostat                              556             258-1200           \>1000                       
  Belinostat                               740             426-1294           \>1000                       
  Naphthohydro. acid                       778             335-1810           \>1000                       
  Droxinostat                              \>1000                             \>1000                       
  CAY10603                                 \>1000                             \>1000                       
  VAHA                                     \>1000                             \>1000                       
  MC-1568                                  \>1000                             \>1000                       
  ABHA                                     \>1000                             \>1000                       
  NW58                                     \>1000                             \>1000                       
  Tubacin                                  \>1000                             \>1000                       
  HPOB                                     \>1000                             \>1000                       
  BRD73954                                 \>1000                             \>1000                       
  CUDC-101                                 \>1000                             \>1000                       
  Rocilinostat                             \>1000                             \>1000                       
  Tubastatin A                             \>1000                             \>1000                       
  PCI-34051                                \>1000                             \>1000                       
  Cyclic depsipeptide                      Romidepsin      0.124              0.103--0.149    0.196        0.102--0.374
  Benzamides                               Entinostat      680                475--974        640          200-2056
  Mocetinostat                             \>1000                             \>1000                       
  Thioester                                KD5170          40.6               20.6--79.9      75.3         52.6--107.9
  Disulfide                                Psammaplin A    56.3               22.9--138.3     93.4         55.1--158.1
  Thiolate                                 TCS HDAC620b    284                171--470        \>1000       
  Cyclic tetrapeptide                      Apicidin        83.3               51.5--134.5     489          218-1097
  Fatty acids                              Valproic acid   \>1000                             \>1000       
  AN-9                                     \>1000                             \>1000                       
  Sesquiterpene lactone                    Parthenolide    \>1000                             \>1000       
  **2) Commercial blowfly insecticides**                                                                   
  Pyrimidine                               Dicyclanil      0.115              0.0160--0.829   0.0634       0.0519--0.0776
  Diamino-triazine                         Cyromazine      1.27               0.673--2.40     1.54         0.600--3.96
  Benzoyl phenyl urea                      Diflubenzuron   0.230              0.133--0.400    0.119        0.0941--0.151

###### 

Effects of HDACi on HDAC activity of nuclear extracts from blowfly eggs.

Table 3

  Drug group              Compound        Nuclear extract assay   
  ----------------------- --------------- ----------------------- ------------------
  Hydroxamic acids        Trichostatin    0.016                   0.011--0.022
  CUDC-907                0.11            0.08--0.17              
  AR-42                   0.21            0.18--0.26              
  Quisinostat             0.009           0.003--0.022            
  Nexturostat             5.1             3.2--8.3                
  Panobinostat            0.017           0.012--0.025            
  Pracinostat             0.69            0.58--0.82              
  SBHA                    9.9             6.5--15.2               
  SAHA                    0.39            0.30--0.50              
  Givinostat              0.19            0.15--0.24              
  M344                    0.58            0.41--0.81              
  Resminostat             1.71            1.27--2.30              
  Belinostat              0.27            0.19--0.36              
  Naphthohydro. acid      83              54--128                 
  Droxinostat             49              40--59                  
  CAY10603                0.17            0.10--0.27              
  VAHA                    \>100                                   
  ABHA                    2.6             1.5--4.6                
  Tubacin                 26              18--37                  
  HPOB                    17              13--20                  
  BRD73954                \>100                                   
  CUDC-101                0.032           0.014--0.070            
  Rocilinostat            2.0             1.6--2.4                
  Tubastatin A            71              37--133                 
  PCI-34051               \>100                                   
  Cyclic depsipeptide     Romidepsin      0.000014                0.00001--0.00002
  Benzamides              Entinostat      15                      5--46
  Mocetinostat            \>100                                   
  Thioester               KD5170          0.41                    0.32--0.50
  Disulfide               Psammaplin A    0.015                   0.007--0.032
  Thiolate                TCS HDAC620b    \>100                   
  Cyclic tetrapeptide     Apicidin        0.72                    0.45--1.14
  Fatty acid              Valproic acid   \>100                   
  Sesquiterpene lactone   Parthenolide    \>100                   

[^1]: These authors contributed equally to the study.
